Maintaining Safety with SARS-CoV-2 Vaccines. Lunes 18 de enero

De

Maintaining Safety with SARS-CoV-2 Vaccines


Authors: 

  • Mariana C. Castells, M.D., Ph.D., 
  • and Elizabeth J. Phillips, M.D.

    • Abstract

     To date, the development of mRNA vaccines for the prevention of infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a success story, with no serious concerns identified in the ongoing phase 3 clinical trials.1 Minor local side effects such as pain, redness, and swelling have been observed more frequently with the vaccines than with placebo. Systemic symptoms such as fever, fatigue, headache, and muscle and joint pain have also been somewhat more common with the vaccines than with placebo, and most have occurred during the first 24 to 48 hours after vaccination.1 In the phase 1–3 clinical trials of the Pfizer–BioNTech and Moderna mRNA vaccines, potential participants with a history of an allergic reaction to any component of the vaccine were excluded. The Pfizer–BioNTech studies also excluded participants with a history of severe allergy associated with any vaccine (see the protocols of the two trials, available with the full text of the articles at NEJM.org, for full exclusion criteria).1,2 Hypersensitivity adverse events were equally represented in the placebo (normal saline) and vaccine groups in both trials.

    DOI 10.1056/NEJMra2035343

    Comentarios

    Publicar un comentario

    Entradas populares de este blog

    La biopsia cutánea en la urticaria crónica: cuándo realizarla, qué buscar y dónde hacerlo

    De
    La biopsia cutánea en la urticaria crónica: cuándo realizarla, qué buscar y dónde hacerlo Autores: A. López Mateos, M.J. Sánchez Pujol y J.F. Silvestre Salvador Resumen: La urticaria crónica es una entidad relativamente frecuente en la práctica clínica habitual, cuyo diagnóstico se establece de forma clínica. Sin embargo, existen ocasiones en las que está indicada la realización de una biopsia cutánea para confirmar el diagnóstico y diferenciarla de otras patologías que pueden cursar con erupciones urticariformes. En este trabajo revisamos los hallazgos histopatológicos que podemos encontrar tanto en la urticaria crónica como en las patologías que plantean un diagnóstico diferencial. Con base en ello, proponemos un algoritmo que recoge las indicaciones para realizar una biopsia cutánea y la orientación del diagnóstico en función de los hallazgos histopatológicos que encontremos en la misma. DOI:   https://doi.org/10.1016/j.ad.2020.11.016
    Leer más

    Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management. Fecha: Miércoles 12 de junio

    De
    Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management. Authors: Castells M1, Butterfield J2. 1 Division of Rheumatology, Allergy, and Immunology, Brigham and Women's Hospital Mastocytosis Center, Boston, Mass. Electronic address: mcastells@bwh.harvard.edu. 2 Mayo Clinic Program for Mast Cell and Eosinophil Disorders, Mayo Clinic, Rochester, Minn. Abstract: Patients with clonal mast cell activation syndromes (MCAS) including cutaneous and systemic mastocytosis (SM) may present with symptoms of mast cell activation, but in addition can have organ damage from the local effects of tissue infiltration by clonal mast cells. Patients with nonclonal MCAS may have chronic or episodic mast cell activation symptoms with an increase in serum tryptase and/or urinary metabolites of histamine, prostaglandin D2, and leukotrienes. Symptoms of MCAS and SM can be managed by blockade of mediator receptors (H1 and H2 antihistamines, leukotriene r...
    Leer más

    Skin bacterial transplant in atopic dermatitis: Knowns, unknowns and emerging trends. Miércoles 21 de agosto

    De
    Skin bacterial transplant in atopic dermatitis: Knowns, unknowns and emerging trends. Authors:  Hendricks AJ1, Mills BW2, Shi VY3. 1 University of Arizona College of Medicine, Tucson, AZ USA. 2 Texas Tech Health Sciences Center El Paso Paul L. Foster School of Medicine, El Paso, TX USA. 3 University of Arizona Department of Medicine, Division of Dermatology, Tucson, AZ USA. Electronic address: vshi@email.arizona.edu. Abstract: Dysbiosis is a key pathogenic factor in the cycle of  skin  barrier impairment and inflammation in  atopic   dermatitis  (AD).  Skin  microbial composition in AD is characterized by increased presence of Staphylococcus aureus (S. aureus) and decrease in microbial diversity and commensal  bacterial  species. Attenuation of S. aureus-driven inflammation aids in breaking the itch-scratch cycle via modulation of the cutaneous immune response.  Skin   bacterial   transplant  (SBT), a f...
    Leer más